The Role of Community Advisory Committees in Clinical Trials of Anti-HIV Agents

1988 ◽  
Vol 10 (4) ◽  
pp. 5 ◽  
Author(s):  
Ronald O. Valdiserri ◽  
Geraldine Maiatico Tama ◽  
Monto Ho
Keyword(s):  
Clinical Trials ◽  
Advisory Committees ◽  
Anti Hiv Agents ◽  
Anti Hiv

The antiviral lectin cyanovirin-N: probing multivalency and glycan recognition through experimental and computational approaches

2013 ◽  
Vol 41 (5) ◽  
pp. 1170-1176 ◽  
Author(s):  
Brian W. Woodrum ◽  
Jason D. Maxwell ◽  
Ashini Bolia ◽  
S. Banu Ozkan ◽  
Giovanna Ghirlanda
Keyword(s):  
Viral Entry ◽  
High Specificity ◽  
Integrated Approach ◽  
Protein Gp120 ◽  
Computational Work ◽  
Gp120 Glycoprotein ◽  
Anti Hiv Agents ◽  
Anti Hiv ◽  
Envelope Protein Gp120

CVN (cyanovirin-N), a small lectin isolated from cyanobacteria, exemplifies a novel class of anti-HIV agents that act by binding to the highly glycosylated envelope protein gp120 (glycoprotein 120), resulting in inhibition of the crucial viral entry step. In the present review, we summarize recent work in our laboratory and others towards determining the crucial role of multivalency in the antiviral activity, and we discuss features that contribute to the high specificity and affinity for the glycan ligand observed in CVN. An integrated approach that encompasses structural determination, mutagenesis analysis and computational work holds particular promise to clarify aspects of the interactions between CVN and glycans.

Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents

2013 ◽  
Vol 439 (2) ◽  
pp. 221-227 ◽  
Author(s):  
Yumi Hashiguchi ◽  
Akinobu Hamada ◽  
Takashi Shinohara ◽  
Kiyoto Tsuchiya ◽  
Hirofumi Jono ◽  
...  
Keyword(s):  
T Cells ◽  
Cd4 T Cells ◽  
Intestinal Cells ◽  
P Glycoprotein ◽  
Anti Hiv Agents ◽  
Anti Hiv ◽  
Human Intestinal Cells

Advances of Research on Anti-HIV Agents from Traditional Chinese Herbs

2011 ◽  
Vol 23 (1) ◽  
pp. 67-75 ◽  
Author(s):  
Y. Chu ◽  
H. Liu
Keyword(s):  
Clinical Trials ◽  
Chinese Medicine ◽  
Antiretroviral Therapy ◽  
Side Effects ◽  
Highly Active Antiretroviral Therapy ◽  
People Living With Hiv ◽  
Highly Active ◽  
Living With Hiv ◽  
Anti Hiv Agents ◽  
Anti Hiv

The current approach for dealing with the global pandemic of AIDS focuses on pharmaceuticals. The classic treatment of AIDS is highly active antiretroviral therapy, but most people living with HIV/AIDS—especially those in developing countries—have little or no access to the treatment because of the high cost of the therapy. Such treatment is associated with toxic side effects and drug resistance. As such, the search for better anti-HIV agents continues, with much attention focused on natural sources—particularly, plant species. Thousands of herbs have been screened for anti-HIV activity, and new compounds have been discovered from the extracts, many of which demonstrate inhibitory activity against HIV. Their mechanisms of action include inhibiting the activities of reverse transcriptase, protease, and integrase; weakening infection at the level of viral entry; and downregulating related gene expression. This provides researchers with new clues to synthesize drugs for the anti-HIV battle. Some synthetic derivatives of the anti-HIV natural products have stronger inhibitory effects in vitro than do their natural counterparts. Various mixed preparations of these anti-HIV herbs are in clinical trials or are applied in the treatment of people living with HIV/AIDS—some of which yield lower plasma viral load, enhance immune function, relieve related symptoms and signs, improve the quality of life, or, in combination with highly active antiretroviral therapy, alleviate the side effects of biomedical drugs. This article reviews current laboratory findings and clinical trials of anti-HIV agents from traditional herbs—particularly, herbs in traditional Chinese medicine. Drug interactions with highly active antiretroviral therapy and criteria for clinical evaluation of traditional Chinese medicine treatment are also discussed.

Bridging the Knowledge Gaps in Arrhythmogenic Cardiovascular Conditions: The Critical Role of Registries

2016 ◽  
Vol 10 (2) ◽  
pp. 1 ◽  
Author(s):  
Melody Hermel ◽  
Rebecca Duffy ◽  
Alexander Orfanos ◽  
Isabelle Hack ◽  
Shayna McEnteggart ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Natural History ◽  
Risk Stratification ◽  
Critical Role ◽  
Knowledge Gaps ◽  
Level Of Evidence ◽  
The Future

Cardiac registries have filled many gaps in knowledge related to arrhythmogenic cardiovascular conditions. Despite the less robust level of evidence available in registries when compared with clinical trials, registries have contributed a range of clinically useful information. In this review, the authors discuss the role that registries have played – related to diagnosis, natural history, risk stratification, treatment, and genetics of arrhythmogenic cardiovascular conditions – in closing knowledge gaps, and their role in the future.

Сatalytic Phosphorylation of Aromatic C-H Bonds: from Traditional Approaches to Electrochemistry

2019 ◽  
Vol 23 (16) ◽  
pp. 1756-1770
Author(s):  
Sofia Strekalova ◽  
Mikhail Khrizanforov ◽  
Oleg Sinyashin ◽  
Yulia Budnikova
Keyword(s):  
Organophosphorus Compounds ◽  
Normal Pressure ◽  
Acid Group ◽  
Synthetic Methods ◽  
Heteroaromatic Compounds ◽  
Anti Cancer ◽  
Phosphonic Acid Group ◽  
Traditional Approaches ◽  
Anti Hiv Agents ◽  
Anti Hiv

The interest in organophosphorus compounds with a C-P bond is due to their wide use in various fields, especially in medicine and agrochemistry. Prominent examples of anti-cancer, antibacterial, and anti-HIV agents are therapeutic candidates containing a phosphonic acid group fragment. This review provides modern synthetic methods for obtaining phosphorylated aromatic and heteroaromatic compounds with the participation of complexes and salts of various metals developed in recent years as well modern protocol - electrochemical synthesis which allows carrying out reactions at room temperature and normal pressure with no additional oxidants or bases. Herein, we demonstrate new trends and evolution of phosphorylation reactions in catalysis.

PD-L1 Inhibitors for the Treatment of Prostate Cancer

2020 ◽  
Vol 21 (15) ◽  
pp. 1558-1565
Author(s):  
Matteo Santoni ◽  
Francesco Massari ◽  
Liang Cheng ◽  
Alessia Cimadamore ◽  
Marina Scarpelli ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Trials ◽  
T Lymphocytes ◽  
Chronic Inflammation ◽  
Immune Cells ◽  
Response To Therapy ◽  
Complex Series

The carcinogenesis of prostate cancer (PCa) results from a complex series of events. Chronic inflammation and infections are crucial in this context. Infiltrating M2 type macrophages, as well as neutrophils and T lymphocytes, contribute to PCa development, progression and response to therapy. The preliminary findings on the efficacy of immunotherapy in patients with PCa were not encouraging. However, a series of studies investigating anti-PD-L1 agents such as Atezolizumab, Avelumab and Durvalumab used alone or in combination with other immunotherapies, chemotherapy or locoregional approaches are in course in this tumor. In this review, we illustrate the role of immune cells and PD-L1 expression during PCa carcinogenesis and progression, with a focus on ongoing clinical trials on anti-PD-L1 agents in this context.

Marine Natural Products as Lead Anti-HIV Agents

2003 ◽  
Vol 3 (5) ◽  
pp. 401-424 ◽  
Author(s):  
D. Gochfeld ◽  
K. El Sayed ◽  
M. Yousaf ◽  
J. Hu ◽  
P. Bartyzel ◽  
...  
Keyword(s):  
Natural Products ◽  
Marine Natural Products ◽  
Anti Hiv Agents ◽  
Anti Hiv

ACE2/Angiotensin-(1-7)/Mas Receptor Axis in Human Cancer: Potential Role for Pediatric Tumors

2020 ◽  
Vol 21 (9) ◽  
pp. 892-901 ◽  
Author(s):  
Ana Luiza Ataide Carneiro de Paula Gonzaga ◽  
Vitória Andrade Palmeira ◽  
Thomas Felipe Silva Ribeiro ◽  
Larissa Braga Costa ◽  
Karla Emília de Sá Rodrigues ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Angiotensin Ii ◽  
Pediatric Cancer ◽  
Pediatric Patients ◽  
Human Cancer ◽  
Experimental Studies ◽  
At1 Receptor ◽  
Pediatric Tumors ◽  
Mas Receptor

Background: Pediatric tumors remain the highest cause of death in developed countries. Research on novel therapeutic strategies with lesser side effects is of utmost importance. In this scenario, the role of Renin-Angiotensin System (RAS) axes, the classical one formed by angiotensinconverting enzyme (ACE), Angiotensin II and AT1 receptor and the alternative axis composed by ACE2, Angiotensin-(1-7) and Mas receptor, have been investigated in cancer. Objective: This review aimed to summarize the pathophysiological role of RAS in cancer, evidence for anti-tumor effects of ACE2/Angiotensin-(1-7)/Mas receptor axis and future therapeutic perspectives for pediatric cancer. Methods: Pubmed, Scopus and Scielo were searched in regard to RAS molecules in human cancer and pediatric patients. The search terms were “RAS”, “ACE”, “Angiotensin-(1-7)”, “ACE2”, “Angiotensin II”, “AT1 receptor”, “Mas receptor”, “Pediatric”, “Cancer”. Results: Experimental studies have shown that Angiotensin-(1-7) inhibits the growth of tumor cells and reduces local inflammation and angiogenesis in several types of cancer. Clinical trials with Angiotensin-( 1-7) or TXA127, a pharmaceutical grade formulation of the naturally occurring peptide, have reported promising findings, but not enough to recommend medical use in human cancer. In regard to pediatric cancer, only three articles that marginally investigated RAS components were found and none of them evaluated molecules of the alternative RAS axis. Conclusion: Despite the potential applicability of Angiotensin-(1-7) in pediatric tumors, the role of this molecule was never tested. Further clinical trials are necessary, also including pediatric patients, to confirm safety and efficiency and to define therapeutic targets.

Sign in / Sign up

Export Citation Format

Share Document